Melanoma - Targeted Therapeutics

Table of Contents

1 Executive Summary

2 About Cancer Highlights

3 Methodologies

4 Table of Contents

• 4.1 List of Boxes
• 4.2 List of Tables

5 Etiology and Pathophysiology

6 Current Treatment Strategies

• 6.1 An Overview
• 6.2 Cytotoxic Drugs
  • 6.2.1 Dacarbazine
  • 6.2.2 Cisplatin
  • 6.2.3 Carboplatin
  • 6.2.4 Carmustine
  • 6.2.5 Melphalan
  • 6.2.6 Paclitaxel
  • 6.2.7 Tamoxifen
  • 6.2.8 Temozolomide
  • 6.2.9 Vinblastine/Vinorelbine
• 6.3 Biological treatments
  • 6.3.1 Intron A
  • 6.3.2 Virulizin
  • 6.3.3 Melacine
  • 6.3.4 Alfanative (Multiferon)
  • 6.3.5 Proleukin or (Macrolin)
  • 6.3.6 Enhanzyn
  • 6.3.7 M-VAX
• 6.4 Other
  • 6.4.1 Ceplene Maxamine

7 Key Therapy Strategies

• 7.1 Immunotherapy
• 7.2 Anti-angiogenesis
• 7.3 Apoptotic Induction
• 7.4 Gene Therapy

8 Current Melanoma Drug Development: Late Stage Pipeline

• 8.1 Immunotherapy
  • 8.1.1 Oncophage
  • 8.1.2 Canvaxin
  • 8.1.3 GMK
  • 8.1.4 MDX-010
  • 8.1.5 OncoVax
  • 8.1.6 ALLOVECTIN-7
  • 8.1.7 Peginterferon alfa-2b
• 8.2 Anti-angiogenesis
  • 8.2.1 Lenalidomide
• 8.3 Apoptotic Inducers
  • 8.3.1 Genasense
• 8.4 Inhibiting Cell Growth
  • 8.4.1 Temozolomide

9 Current Melanoma Drug Development: Early Stage Pipeline

• 9.1 Immunotherapy
  • 9.1.1 INGN 241
  • 9.1.2 QS-21
  • 9.1.3 Talabostat
  • 9.1.4 SB 249553
  • 9.1.5 GVAX
  • 9.1.6 GV 1001
  • 9.1.7 Dexosome
  • 9.1.8 Uvidem
  • 9.1.9 NY-ESO-1 ISCOMS
  • 9.1.10 NOVOVAC-M1
  • 9.1.11 Oxxon Vaccine
  • 9.1.12 Therion' s Melanoma Vaccine
  • 9.1.13 ImmunoVex trimelan
  • 9.1.14 OncoVEXGM-CSF
  • 9.1.15 Zadaxin
  • 9.1.16 Alvac-Mage1/Mage3
  • 9.1.17 Iboctadekin
  • 9.1.18 ProMune
  • 9.1.19 BAY 504798
  • 9.1.20 EMD 273063
• 9.2 Antiangiogenesis
  • 9.2.1 Sorafenib
  • 9.2.2 Vitaxin
  • 9.2.3 Avastin
  • 9.2.4 PI 88
• 9.3 Apoptotic Inducers
  • 9.3.1 Didemnin B
  • 9.3.2 KOS 953
• 9.4 Small Molecules Inhibiting Cell Growth
  • 9.4.1 Pivanex
  • 9.4.2 Karenitecin
  • 9.4.3 Lomeguatrib
  • 9.4.4 PD 0325901
  • 9.4.5 SB 715992
  • 9.4.6 INO 1001
  • 9.4.7 CP 4055
• 9.5 Other Biological Drugs
  • 9.5.1 AP 12009
  • 9.5.2 Ecromeximab
  • 9.5.3 ILX 651
  • 9.5.4 Kahalalide F
  • 9.5.5 ABX MA1
  • 9.5.6 MJV 101
  • 9.5.7 A Russian Melanoma Vaccine
  • 9.5.8 Elea Vaccine
  • 9.5.9 F 50040

10 Appendix I: Treatment Guide Lines Melanoma

11 Disclaimer

12 Drug Index

13 Company Index

List of Boxes

• Box 1: Quick Facts - Enhanzyn
• Box 2: Quick Facts - M-VAX
• Box 3: M-VAX - Business & Market Bakground
• Box 4: Mechanisms which Tumor Cells use to Evade an Immune Reaction
• Box 5: Introgen' s INGN 241 Shows Vaccine Properties
• Box 6: Quick Facts - Oncophage
• Box 7: Oncophage - Designation and Status
• Box 8: Quick Facts - Canvaxin
• Box 9: Canvaxin - Designation and Status
• Box 10: CancerVax Milestone payment
• Box 11: Quick Facts - GM2-KLH Vaccine
• Box 12: Progenics Reaquires Rights to Vaccine
• Box 13: Completed Melanoma Phase III trials
• Box 14: Quick Facts - MDX-010
• Box 15: Quick Facts -OncoVax
• Box 16: Quick Facts - ALLOVECTIN-7
• Box 17: Quick Facts - Peginterferon alfa-2b
• Box 18: Introgen' s INGN 241 Shows Anti-angiogenesis Properties
• Box 19: Quick Facts - Lenalidomide
• Box 20: Quick Facts - Oblimersen
• Box 21: Quick Facts - Temozomide
• Box 22: Molecular Pathways Underlying the Activity of Temozolomide' s Anti-Cancer Therapy
• Box 23: Regulatory Progress
• Box 24: Quick Facts - INGN 241
• Box 25: Molecular Pathways Underlying Activity of Introgen' s INGN 241 Anti-Cancer Therapy
• Box 26: Quick Facts - QS-21
• Box 27: Quick Facts - Talabostat
• Box 28: Quick Facts - SB 249553
• Box 29: Quick Facts - GVAX
• Box 30: Agreement Japan Tobacco and Cell Genesys
• Box 31: Predicted launch of GVAX
• Box 32: Quick Facts - GV 1001
• Box 33: Quick Facts - Dexosome
• Box 34: Important Milestones and License Fees
• Box 35: Quick Facts - Uvidem
• Box 36: Agreements Between Sanofi-Aventis and IDM
• Box 37: Quick Facts - NY-ESO-1 ISCOMS
• Box 38: NY-ESO-1 and ISCOMATRIX
• Box 39: Quick Facts - NovoVac-M1
• Box 40: Quick Facts - Oxxon vaccine
• Box 41: Quick Facts - Therion' s Melanoma Vaccine
• Box 42: Quick Facts - ImmunoVEX trimelan
• Box 43: Quick Facts - OncoVEX GM-CSF
• Box 44: Quick Facts - ZADAXIN
• Box 45: Developmental History Thymosin alpha1
• Box 46: Quick Facts - Alvac-Mage1/Mage3
• Box 47: Quick Facts - iboctadekin
• Box 48: Quick Facts - PF-3512676
• Box 49: Quick Facts - BAY-504798
• Box 50: Quick Facts - EMD-273063
• Box 51: Quick Facts - Sorefenib
• Box 52: Quick Facts - Vitaxin
• Box 53: Quick Facts . Bevacizumab
• Box 54: Quick Facts - PI88
• Box 55: Quick Facts - Didemnin B
• Box 56: Quick Facts - KOS 953
• Box 57: Quick Facts - Pivanex
• Box 58: Quick Facts - Karenitecin
• Box 59: Company Statement
• Box 60: Quick Facts - Lomeguatrib
• Box 61: Quick Facts - PD 0325901
• Box 62: Quick Facts - SB 715992
• Box 63: Quick Facts - INO 1001
• Box 64: Quick Facts - CP 4055
• Box 65: Quick Facts - AP 12009
• Box 66: Quick Facts - Ecromeximab
• Box 67: Quick Facts - ILX 651
• Box 68: Quick Facts - Kahalalide F
• Box 69: Quick Facts - ABX MA1
• Box 70: Quick Facts - MJV 101
• Box 71: Quick Facts - Russian Melanoma Vaccine
• Box 72: Quick Facts - N-Acetyl-GM3 ganglioside
• Box 73: Quick Facts - F 50040
• Box 74: KpOmpA Technology

List of Tables

• Table 1: Critical Risk Factors for Development of Melanoma
• Table 2: Definition and Description of Stages of Melanoma
• Table 3: Prognosis of the 4 Stages of Malignant Melanoma
• Table 4: Current Cytotoxic Drugs for the Treatment of Melanoma
• Table 5: Progress Profile Dacarbazine
• Table 6: Progress Profile Cisplatin
• Table 7: Progress Profile Carboplatin
• Table 8: Progress Profile Carmustine
• Table 9: Progress Profile Melphalan
• Table 10: Progress Profile Paclitaxel
• Table 11: Progress Profile Tamoxifen
• Table 12: Progress Profile Temozolomide
• Table 13: Progress Profile Vinblastine/Vinorelbine
• Table 14: Progress Profile Interferon alfa-2b
• Table 15: Development Milestones- Virulizin
• Table 16: Development Milestones - Melacine
• Table 17: Development Milestones - Alfanative
• Table 18: Development Milestones - Proleukin
• Table 19: Deployed Strategies for Blocking Angiogenesis
• Table 20: Phase III Randomized Studies of Melanoma Vaccines.
• Table 21: Tumor antigen based vaccines
• Table 22: In vivo Gene Therapy
• Table 23: Cell Therapy Based Platform in Pipeline as Potential Treatment of Melanoma
• Table 24: Ex vivo gene therapy loading of antigen presenting cells
• Table 25: Overview of Immunostimulants in Development based on Type
• Table 26: Overview of Immuno-Biologicals
• Table 27: Overview of Gene Therapy Drugs for Immunostimulation
• Table 28: MDX-010' s Collaborative History and Landscape
• Table 29: Anti-angiogenisis Drugs under Development
• Table 30: Overview Apoptopic Inducer Drugs
• Table 31: Overview of Small Molecule Drugs
• Table 32: Selected Regulatory Progress of Sorafenib
• Table 33: Selected Regulatory Progress of Didemin B
• Table 34: Overview of Various Biological Drugs in Development for Melanoma